Rheumatology (Oxford). 2019 Nov 1;58(Supplement_6):vi44-vi55. doi: 10.1093/rheumatology/kez294.
Current and future advances in genetic testing in systemic autoinflammatory diseases.
Author information
- 1
- Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract
Systemic autoinflammatory diseases (SAIDs) are a group of inflammatory disorders caused by dysregulation in the innate immune system that leads to enhanced immune responses. The clinical diagnosis of SAIDs can be difficult since individually these are rare diseases with considerable phenotypic overlap. Most SAIDs have a strong genetic background, but environmental and epigenetic influences can modulate the clinical phenotype. Molecular diagnosis has become essential for confirmation of clinical diagnosis. To date there are over 30 genes and a variety of modes of inheritance that have been associated with monogenic SAIDs. Mutations in the same gene can lead to very distinct phenotypes and can have different inheritance patterns. In addition, somatic mutations have been reported in several of these conditions. New genetic testing methods and databases are being developed to facilitate the molecular diagnosis of SAIDs, which is of major importance for treatment, prognosis and genetic counselling. The aim of this review is to summarize the latest advances in genetic testing for SAIDs and discuss potential obstacles that might arise during the molecular diagnosis of SAIDs.
© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.
KEYWORDS:
NGS; autoinflammatory diseases; digenic inheritance; gene panel; genetic testing; mosaicism
- PMID:
- 31769854
- PMCID:
- PMC6878845
- DOI:
- 10.1093/rheumatology/kez294
No hay comentarios:
Publicar un comentario